Valuation: Sangamo Therapeutics, Inc.

Market Cap 41.93M 37.32M 34.59M 31.34M 58.9M 3.97B 59.89M 415M 163M 2.08B 157M 154M 6.63B P/E 2024
-2.1x
P/E 2025 -0.96x
Enterprise Value 47.77M 42.52M 39.41M 35.71M 67.12M 4.53B 68.24M 473M 186M 2.37B 179M 175M 7.56B EV / Sales 2024
3.49x
EV / Sales 2025 3.72x
Free-Float
99.07%
Yield 2024 *
-
Yield 2025 -
1 day+8.70%
1 week-21.48%
Current month-25.17%
1 month-22.15%
3 months+46.86%
6 months-59.27%
Current year-73.81%
1 week 0.01
Extreme 0.01
0.15
1 month 0.01
Extreme 0.01
0.16
Current year 0.01
Extreme 0.01
0.6
1 year 0.01
Extreme 0.01
0.69
3 years 0.01
Extreme 0.01
3.18
5 years 0.01
Extreme 0.01
11.49
10 years 0.01
Extreme 0.01
27.5
Manager TitleAgeSince
Chief Executive Officer 63 2016-05-31
Director of Finance/CFO 47 2026-02-02
Chief Tech/Sci/R&D Officer - 2023-05-28
Director TitleAgeSince
Chairman 70 2017-05-31
Director/Board Member 63 2016-05-31
Director/Board Member 68 2016-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
5/25/26 Tax

General Counsel

-4,036 0.0010%
5/25/26 Tax

Executive/Senior Manager

-4,036 0.0010%
5/25/26 Tax

Chief Executive Officer

-12,613 0.0030%
Change 5-day change 1-year change 3-year change Capi.($)
+8.70%-21.48%-83.70%-78.66% 41.93M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+10.35%+13.02%+87.74% 51.87B
+6.91%+8.57%+6.88%+72.12% 51.2B
+0.15%+1.43%+24.69%+43.42% 43.76B
+3.26%+9.58%+20.07%+131.54% 42.09B
+7.09%+3.82%+262.23%+599.46% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+5.34%+30.98%+26.07% 22.8B
Average +3.49%-2.79%+38.78%+102.10% 37.58B
Weighted average by Cap. +2.87%+0.61%+50.73%+124.00%

Financials

2024 2025
Net sales 57.8M 51.45M 47.68M 43.21M 81.2M 5.48B 82.56M 572M 225M 2.87B 217M 212M 9.14B 39.55M 35.21M 32.63M 29.57M 55.57M 3.75B 56.5M 392M 154M 1.96B 148M 145M 6.26B
Net income -97.94M -87.18M -80.8M -73.21M -138M -9.28B -140M -969M -381M -4.86B -367M -360M -15.49B -123M -109M -101M -91.9M -173M -11.65B -176M -1.22B -478M -6.09B -461M -452M -19.44B
Net Debt -11.35M -10.1M -9.36M -8.49M -15.95M -1.08B -16.22M -112M -44.14M -563M -42.58M -41.7M -1.8B 5.85M 5.2M 4.82M 4.37M 8.21M 554M 8.35M 57.88M 22.74M 290M 21.93M 21.48M 925M
Projected Income Statement - Annual - Sangamo Therapeutics, Inc.
Logo Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company's assets include clinical-stage programs ST-503 for chronic neuropathic pain and giroctocogene fitelparvovec for hemophilia A, as well as its cell therapy and regulatory T cell (T-Reg) assets. The Company is developing ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. ST-503 uses an AAV vector carrying an engineered zinc finger repressor (ZFR) to specifically target the human gene, SCN9A, that encodes the Nav1.7 sodium channel and is critical for pain signaling. Giroctocogene fitelparvovec is a liver-tropic rAAV6 vector carrying a B-domain deleted F8 gene that is delivered through a single IV infusion. The Company is operating under court supervision in Chapter 11.
Employees
142
Date Price Change Volume
26-10-20 US$0.1100 +8.70% 100,620
26-10-19 US$0.1012 -8.17% 1,896,966
26-10-16 US$0.1102 -21.79% 1,967,535
26-10-15 US$0.1409 +0.71% 3,569,256
26-10-14 US$0.1399 -0.14% 3,471,665
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Sangamo Therapeutics, Inc.

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sangamo Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SGMOQ Stock